Literature DB >> 18006642

Vascular endothelial growth factor receptor-2 expression is down-regulated by 17beta-estradiol in MCF-7 breast cancer cells by estrogen receptor alpha/Sp proteins.

Kelly J Higgins1, Shengxi Liu, Maen Abdelrahim, Kathryn Vanderlaag, Xinyi Liu, Weston Porter, Richard Metz, Stephen Safe.   

Abstract

17beta-Estradiol (E2) induces and represses gene expression in breast cancer cells; however, the mechanisms of gene repression are not well understood. In this study, we show that E2 decreases vascular endothelial growth factor receptor 2 (VEGFR2) mRNA levels in MCF-7 cells, and this gene was used as a model for investigating pathways associated with E2-dependent gene repression. Deletion analysis of the VEGFR2 promoter indicates that the proximal GC-rich motifs at -58 and -44 are critical for the E2-dependent decreased response in MCF-7 cells. Mutation or deletion of these GC-rich elements results in loss of hormone responsiveness and shows that the -60 to -37 region of the VEGFR2 promoter is critical for both basal and hormone-dependent decreased VEGFR2 expression in MCF-7 cells. Western blot, immunofluorescent staining, RNA interference, and EMSAs support a role for Sp proteins in hormone-dependent down-regulation of VEGFR2 in MCF-7 cells, primarily through estrogen receptor (ER)alpha/Sp1 and ERalpha/Sp3 interactions with the VEGFR2 promoter. Using chromatin immuno-precipitation and transient transfection/RNA interference assays we show that the ERalpha/Sp protein-promoter interactions are accompanied by recruitment of the co-repressors SMRT (silencing mediator of retinoid and thyroid hormone receptor) and NCoR (nuclear receptor corepressor) to the promoter and that SMRT and NCoR knockdown reverse E2-mediated down-regulation of VEGFR2 expression in MCF-7 cells. This study illustrates that both SMRT and NCoR are involved in E2-dependent repression of VEGFR2 in MCF-7 cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18006642      PMCID: PMC2234589          DOI: 10.1210/me.2007-0319

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  68 in total

1.  Combinatorial roles of the nuclear receptor corepressor in transcription and development.

Authors:  K Jepsen; O Hermanson; T M Onami; A S Gleiberman; V Lunyak; R J McEvilly; R Kurokawa; V Kumar; F Liu; E Seto; S M Hedrick; G Mandel; C K Glass; D W Rose; M G Rosenfeld
Journal:  Cell       Date:  2000-09-15       Impact factor: 41.582

2.  Molecular analysis of the inhibition of monocyte chemoattractant protein-1 gene expression by estrogens and xenoestrogens in MCF-7 cells.

Authors:  H Inadera; T Sekiya; T Yoshimura; K Matsushima
Journal:  Endocrinology       Date:  2000-01       Impact factor: 4.736

3.  Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.

Authors:  Erika Krasnickas Keeton; Myles Brown
Journal:  Mol Endocrinol       Date:  2005-03-31

4.  Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription.

Authors:  Y Shang; X Hu; J DiRenzo; M A Lazar; M Brown
Journal:  Cell       Date:  2000-12-08       Impact factor: 41.582

5.  Antioxidant effect of estrogen on cytomegalovirus-induced gene expression in coronary artery smooth muscle cells.

Authors:  E Speir; Z X Yu; K Takeda; V J Ferrans; R O Cannon
Journal:  Circulation       Date:  2000-12-12       Impact factor: 29.690

6.  Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor alpha and Sp3 proteins.

Authors:  M Stoner; F Wang; M Wormke; T Nguyen; I Samudio; C Vyhlidal; D Marme; G Finkenzeller; S Safe
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

7.  The role of CBP in estrogen receptor cross-talk with nuclear factor-kappaB in HepG2 cells.

Authors:  D C Harnish; M S Scicchitano; S J Adelman; C R Lyttle; S K Karathanasis
Journal:  Endocrinology       Date:  2000-09       Impact factor: 4.736

8.  Vascular endothelial growth factor receptor-2: counter-regulation by the transcription factors, TFII-I and TFII-IRD1.

Authors:  Tanisha A Jackson; Harry E Taylor; Deva Sharma; Stephen Desiderio; Sonye K Danoff
Journal:  J Biol Chem       Date:  2005-06-07       Impact factor: 5.157

9.  AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

Authors:  Stephen R Wedge; Jane Kendrew; Laurent F Hennequin; Paula J Valentine; Simon T Barry; Sandra R Brave; Neil R Smith; Neil H James; Michael Dukes; Jon O Curwen; Rosemary Chester; Janet A Jackson; Sarah J Boffey; Lyndsey L Kilburn; Sharon Barnett; Graham H P Richmond; Peter F Wadsworth; Mike Walker; Alison L Bigley; Sian T Taylor; Lee Cooper; Sarah Beck; Juliane M Jürgensmeier; Donald J Ogilvie
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

10.  A life-long search for the molecular pathways of steroid hormone action.

Authors:  Bert W O'Malley
Journal:  Mol Endocrinol       Date:  2005-06
View more
  19 in total

Review 1.  The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas.

Authors:  Laura Annaratone; Eliano Cascardi; Elena Vissio; Ivana Sarotto; Ewa Chmielik; Anna Sapino; Enrico Berrino; Caterina Marchiò
Journal:  Pathobiology       Date:  2020-04-23       Impact factor: 4.342

2.  Significance of estrogen receptor subtypes in breast tumorigenesis and progression.

Authors:  Weiliang Sun; Chijiang Gu; Minming Xia; Guoping Zhong; Haojun Song; Junming Guo
Journal:  Tumour Biol       Date:  2014-06-11

3.  MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer.

Authors:  Gianpiero Di Leva; Pierluigi Gasparini; Claudia Piovan; Apollinaire Ngankeu; Michela Garofalo; Cristian Taccioli; Marilena V Iorio; Meng Li; Stefano Volinia; Hansjuerg Alder; Tatsuya Nakamura; Gerard Nuovo; Yunlong Liu; Kenneth P Nephew; Carlo M Croce
Journal:  J Natl Cancer Inst       Date:  2010-04-13       Impact factor: 13.506

4.  An exquisite cross-control mechanism among endothelial cell fate regulators directs the plasticity and heterogeneity of lymphatic endothelial cells.

Authors:  Jinjoo Kang; Jaehyuk Yoo; Sunju Lee; Wanli Tang; Berenice Aguilar; Swapnika Ramu; Inho Choi; Hasan H Otu; Jay W Shin; G Paolo Dotto; Chester J Koh; Michael Detmar; Young-Kwon Hong
Journal:  Blood       Date:  2010-03-29       Impact factor: 22.113

5.  Down-regulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex.

Authors:  Atsuo Suzuki; Naomi Sanda; Yuhri Miyawaki; Yuta Fujimori; Takayuki Yamada; Akira Takagi; Takashi Murate; Hidehiko Saito; Tetsuhito Kojima
Journal:  J Biol Chem       Date:  2010-03-03       Impact factor: 5.157

6.  Role of SP transcription factors in hormone-dependent modulation of genes in MCF-7 breast cancer cells: microarray and RNA interference studies.

Authors:  Fei Wu; Ivan Ivanov; Rui Xu; Stephen Safe
Journal:  J Mol Endocrinol       Date:  2008-10-24       Impact factor: 5.098

7.  Influence of VEGFR and LHCGR on endometrial adenocarcinoma.

Authors:  Alexandra C Kölbl; Amelie E Birk; Christina Kuhn; Udo Jeschke; Ulrich Andergassen
Journal:  Oncol Lett       Date:  2016-07-22       Impact factor: 2.967

8.  Repression of ESR1 through actions of estrogen receptor alpha and Sin3A at the proximal promoter.

Authors:  Stephanie J Ellison-Zelski; Natalia M Solodin; Elaine T Alarid
Journal:  Mol Cell Biol       Date:  2009-07-20       Impact factor: 4.272

9.  Up-regulation of type II collagen gene by 17β-estradiol in articular chondrocytes involves Sp1/3, Sox-9, and estrogen receptor α.

Authors:  Laure Maneix; Aurélie Servent; Benoît Porée; David Ollitrault; Thomas Branly; Nicolas Bigot; Noureddine Boujrad; Gilles Flouriot; Magali Demoor; Karim Boumediene; Safa Moslemi; Philippe Galéra
Journal:  J Mol Med (Berl)       Date:  2014-08-02       Impact factor: 4.599

10.  Complex actions of thyroid hormone receptor antagonist NH-3 on gene promoters in different cell lines.

Authors:  Vanya Shah; Phuong Nguyen; Ngoc-Ha Nguyen; Marie Togashi; Thomas S Scanlan; John D Baxter; Paul Webb
Journal:  Mol Cell Endocrinol       Date:  2008-09-26       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.